THE WOODLANDS, Texas, July 13, 2026
Autonomix Medical announced the grant of Canadian Patent No. 3,158,197, titled “Endoscopic Sympathectomy Systems and Methods,” further expanding its global intellectual property portfolio supporting precision nerve-targeted therapies. The newly issued patent strengthens the company’s position in the rapidly growing denervation and neuromodulation market by protecting technologies designed for real-time nerve sensing, mapping, physiological monitoring, and feedback-guided treatment. With the addition of the Canadian patent, Autonomix’s intellectual property portfolio now includes 112 issued or pending patent applications worldwide, reinforcing its long-term strategy of developing innovative technologies capable of improving the diagnosis and treatment of diseases involving the peripheral nervous system. The company stated that the patent complements previously issued patents in the United States and Europe, further extending protection across major international healthcare markets.
Patent Protects Advanced Real-Time Neural Sensing and Mapping Technologies
The newly granted patent covers systems and methods that enable physicians to identify, monitor, and modulate autonomic nerves using minimally invasive technologies equipped with real-time physiological and electrophysiological sensing capabilities. Unlike conventional denervation procedures that rely primarily on anatomical landmarks, the patented platform integrates closed-loop feedback mechanisms that allow clinicians to detect neural activity before, during, and after treatment. This approach is designed to improve procedural precision by enabling accurate nerve localization, continuous monitoring of treatment response, and objective assessment of therapeutic effectiveness. The patented technologies include real-time electrophysiological monitoring, nerve sensing and mapping systems, microelectrode- and microsensor-based surgical devices, feedback-guided neuromodulation, implantable monitoring systems, and methods for evaluating procedural outcomes through physiological measurements.
Technology Supports Multiple Chronic Disease Applications
Autonomix believes the patented technology has broad applicability across numerous diseases associated with autonomic nervous system dysfunction and excessive sympathetic nerve activity. Potential therapeutic applications include hypertension, chronic heart failure, chronic kidney disease, metabolic disorders, chronic pain, and other conditions where targeted neuromodulation or denervation may provide clinical benefit. By incorporating sensing-enabled catheter technologies capable of distinguishing neural signals with greater sensitivity than conventional systems, the company’s platform aims to improve treatment accuracy while reducing procedural variability. The technology is intended to provide physicians with objective physiological feedback throughout treatment, potentially enhancing procedural success and improving patient outcomes across a wide range of nerve-targeted interventions.
Advertisement
Patent Strengthens Long-Term Platform Strategy and Global Market Position
The Canadian patent further reinforces Autonomix Medical’s long-term intellectual property strategy by providing additional protection for its expanding precision neuromodulation platform across major international markets. The company’s patent estate includes broad coverage for nerve sensing, neural signal processing, mapping technologies, controlled micro-ablation, and application-specific innovations spanning multiple organ systems, with patent protection extending into the late 2030s. Autonomix is initially advancing its investigational catheter-based platform for the treatment of severe pancreatic cancer pain while pursuing broader opportunities in cardiology, hypertension, chronic pain management, and other diseases involving the peripheral nervous system. By continuing to expand its global intellectual property portfolio, the company is strengthening the competitive foundation supporting future commercialization of its first-in-class nerve-targeted diagnostic and therapeutic technologies across multiple high-value clinical indications.
Source: Autonomix Medical press release
